Clinical Practice Guideline on Acupuncture and Moxibustion:Migraine(WFAS 007.9-2023)is a clinical practice guideline officially released by the World Federation of Acupuncture-Moxibustion Societies(WFAS)on October 9,2...Clinical Practice Guideline on Acupuncture and Moxibustion:Migraine(WFAS 007.9-2023)is a clinical practice guideline officially released by the World Federation of Acupuncture-Moxibustion Societies(WFAS)on October 9,2023,and is the first international guideline on the treatment of migraine with acupuncture.This international standard was developed under the guidance of rigorous evidence-based methodology,and it contains guideline purpose,scope,applicable population,applicable settings,overview of acupuncture for migraine,guideline development process and recommendations.For promoting the understanding and application of this guideline,this article summarizes a total of 18 recommendations in order to assist clinical decisions for migraine with acupuncture.展开更多
A rapid, sensitive and selective UPLC-MS/MS method was developed to determine paeoniflorin and astragaloside IV, This method was validated via a pharmacokinetic study using rat plasma. The internal standard was clarit...A rapid, sensitive and selective UPLC-MS/MS method was developed to determine paeoniflorin and astragaloside IV, This method was validated via a pharmacokinetic study using rat plasma. The internal standard was clarithromycin. A simple one-step deproteinization procedure was used to prepare plasma samples. Separation was achieved on a CAPCELL CORE ADME CI8 column with a gradient mobile phase consisting of solution A （water containing 0.1% formic acid） and solution B （acetonitrile） at a flow rate of 0.3 mL/min. Multiple reaction monitoring （MRM） was used with an electrospray ionization source （ESI） in positive mode. A good linear response was observed within the ranges of 0.01 to 5.00 ~g/mL for paeoniflorin and 0.000l to 0.05 ~tg/mL for astragaloside IV. The accuracy （RE） was within the range of-3.5% to 6.3%, and the intra- and inter-day precisions （RSD） were within 14.2%. The extraction recoveries were all above 78.9%. The pharmacokinetic study of the two analytes in rats after oral administration of Huangqi Guizhi Wuwu Decoction （HGWD） was successfully completed through this method. The method develooed in this studv will fill a gap in oharmacokinetic studies of HGWD.展开更多
In the present study, we aimed to investigate the frequency of CYP3 A4*18 B genetic polymorphism in Han Chinese populations, and to assess the effect of the CYP3 A4*18 B genetic polymorphism on the pharmacokinetics of...In the present study, we aimed to investigate the frequency of CYP3 A4*18 B genetic polymorphism in Han Chinese populations, and to assess the effect of the CYP3 A4*18 B genetic polymorphism on the pharmacokinetics of tinidazole. A total of 100 healthy volunteers from Han nationalities in China were recruited. DNA was extracted from peripheral leukocytes using a standard protocol. A PCR-RFLP method was developed to detect the alleles of CYP3 A4*18 B. A pharmacokinetic study of tinidazole was then carried out in two groups with CYP3 A4*1/*1(n = 10) and CYP3 A4*1/*18 B(n = 9) genotypes. Concentrations of tinidazole were determined using high-performance liquid chromatography in plasma samples that were collected up to 72 h after drug intake. In this study, 88 healthy volunteers were found with CYP3 A4*1/*1 genotype, and 12 were found with CYP3 A4*1/*18 B genotype. CYP3 A4*18 B/*18 B were absent from all subjects. The allele frequencies of CYP3 A4*18 B were 6%. The pharmacokinetic parameters of CYP3 A4*1/*1 genotype and CYP3 A4*1/*18 B genotype in healthy subjects were as follows: t1/2:(15.92±1.62),(15.77±1.67) h;Cmax:(18.72±3.10),(20.25±3.42) mg/L;tmax:(1.50±0.66),(1.45±0.69) h;Vd/F:(55.73±10.66),(51.30±7.75) L;CL/F:(2.44±0.47),(2.26±0.30) L·h;AUC0–∞:(424.40±82.38),(450.53±69.48) mg·h/L. Collectively, the CYP3 A4*18 B genetic polymorphism did not affect pharmacokinetics of tinidazolein healthy volunteers.展开更多
基金Supported by National Key Research and Development Program of China:2019YFC1712200,2019YFC1712203Independent Project of the Institute of Acupuncture and moxibustion,China Academy of Chinese Medical Sciences:ZZ202219004Science and technology innovation project of China Academy of Chinese Medical Sciences:CI2020A03510。
文摘Clinical Practice Guideline on Acupuncture and Moxibustion:Migraine(WFAS 007.9-2023)is a clinical practice guideline officially released by the World Federation of Acupuncture-Moxibustion Societies(WFAS)on October 9,2023,and is the first international guideline on the treatment of migraine with acupuncture.This international standard was developed under the guidance of rigorous evidence-based methodology,and it contains guideline purpose,scope,applicable population,applicable settings,overview of acupuncture for migraine,guideline development process and recommendations.For promoting the understanding and application of this guideline,this article summarizes a total of 18 recommendations in order to assist clinical decisions for migraine with acupuncture.
文摘A rapid, sensitive and selective UPLC-MS/MS method was developed to determine paeoniflorin and astragaloside IV, This method was validated via a pharmacokinetic study using rat plasma. The internal standard was clarithromycin. A simple one-step deproteinization procedure was used to prepare plasma samples. Separation was achieved on a CAPCELL CORE ADME CI8 column with a gradient mobile phase consisting of solution A （water containing 0.1% formic acid） and solution B （acetonitrile） at a flow rate of 0.3 mL/min. Multiple reaction monitoring （MRM） was used with an electrospray ionization source （ESI） in positive mode. A good linear response was observed within the ranges of 0.01 to 5.00 ~g/mL for paeoniflorin and 0.000l to 0.05 ~tg/mL for astragaloside IV. The accuracy （RE） was within the range of-3.5% to 6.3%, and the intra- and inter-day precisions （RSD） were within 14.2%. The extraction recoveries were all above 78.9%. The pharmacokinetic study of the two analytes in rats after oral administration of Huangqi Guizhi Wuwu Decoction （HGWD） was successfully completed through this method. The method develooed in this studv will fill a gap in oharmacokinetic studies of HGWD.
基金The Research Grant from the 115 Project of Legionary Medical Treatment and Public Health(Grant No.06G023).
文摘In the present study, we aimed to investigate the frequency of CYP3 A4*18 B genetic polymorphism in Han Chinese populations, and to assess the effect of the CYP3 A4*18 B genetic polymorphism on the pharmacokinetics of tinidazole. A total of 100 healthy volunteers from Han nationalities in China were recruited. DNA was extracted from peripheral leukocytes using a standard protocol. A PCR-RFLP method was developed to detect the alleles of CYP3 A4*18 B. A pharmacokinetic study of tinidazole was then carried out in two groups with CYP3 A4*1/*1(n = 10) and CYP3 A4*1/*18 B(n = 9) genotypes. Concentrations of tinidazole were determined using high-performance liquid chromatography in plasma samples that were collected up to 72 h after drug intake. In this study, 88 healthy volunteers were found with CYP3 A4*1/*1 genotype, and 12 were found with CYP3 A4*1/*18 B genotype. CYP3 A4*18 B/*18 B were absent from all subjects. The allele frequencies of CYP3 A4*18 B were 6%. The pharmacokinetic parameters of CYP3 A4*1/*1 genotype and CYP3 A4*1/*18 B genotype in healthy subjects were as follows: t1/2:(15.92±1.62),(15.77±1.67) h;Cmax:(18.72±3.10),(20.25±3.42) mg/L;tmax:(1.50±0.66),(1.45±0.69) h;Vd/F:(55.73±10.66),(51.30±7.75) L;CL/F:(2.44±0.47),(2.26±0.30) L·h;AUC0–∞:(424.40±82.38),(450.53±69.48) mg·h/L. Collectively, the CYP3 A4*18 B genetic polymorphism did not affect pharmacokinetics of tinidazolein healthy volunteers.
